ArticleTherapeutic advances in medical oncology2025
Combination regimens as potential treatment of non-small-cell lung cancer patients with HER2 mutation in the real world: a multicenter study.
Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-small-cell lung cancer (NSCLC) with human epidermal growth factor receptor 2 (HER2) mutations poses significant treatment challenges. While chemotherapy combined with immunotherapy or anti-angiogenic therapy has been explored, no standardized regimen exists for these patients. This study aims to evaluate the efficacy of different treatment regimens for HER2-mutated NSCLC. Objectives: Our study aimed to investigate the survival among NSCLC patients with HER2 mutation who received various treatment regimens in real-world settings, providing insights and guidance for clinical practice. Designs: Survival analyses were conducted on patients who underwent different treatment regimens, including chemotherapy, immunotherapy, tyrosine kinase inhibitors (TKIs), and combination therapies, to evaluate their effectiveness. Methods: This retrospective study included 118 patients diagnosed with HER2 mutations through next-generation sequencing at Zhejiang Cancer Hospital and Jinling Hospital affiliated with Nanjing University Medical School from September 2017 to December 2024. Data on treatment regimens and clinical outcomes, including objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS), were collected. Kaplan-Meier analysis estimated PFS and OS, and Cox regression identified factors influencing PFS. Results: Among the 118 patients, ORR and DCR were 22.9% and 58.5%, respectively. Median PFS and OS were 7.3 and 44.9 months, respectively. Combination therapies significantly improved PFS compared to single chemotherapy or immunotherapy or TKIs group (7.8 vs 5.3 months, Conclusion: Combination regimens, especially C + I + A, significantly improve PFS and offer superior therapeutic benefits for patients with HER2-mutated NSCLC compared to single chemotherapy or immunotherapy or TKIs treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.